Mirum CFO sells 5,000 shares in planned trade

Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions.

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at prices reported between about $121.13 and $124.94 per share, pursuant to a pre-arranged Rule 10b5-1 plan. Following these transactions, he continues to own 42,181 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 4 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 5,000 shs ($611K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,124	$121.67	$380K
Sale	Common Stock	1,048	$122.43	$128K
Sale	Common Stock	528	$123.84	$65K
Sale	Common Stock	300	$124.94	$37K

Holdings After Transaction: Common Stock — 42,181 shares (Direct)

Footnotes (4)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
2. F2. . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. F4. . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Total shares sold: 5,000 shares Sale price: $124.94 per share Sale price: $123.84 per share +5 more

8 metrics

Total shares sold 5,000 shares Common stock sold in open-market transactions on July 6, 2026

Sale price $124.94 per share One of the reported open-market sales of common stock

Sale price $123.84 per share One of the reported open-market sales of common stock

Sale price $122.43 per share One of the reported open-market sales of common stock

Sale price $121.67 per share Weighted average sale price for one transaction batch

Shares held after transactions 42,181 shares Direct ownership of Mirum common stock following reported sales

Largest single sale block 3,124 shares Open-market sale at $121.67 per share

Net share activity 5,000 shares sold Net-sell direction from transaction summary

Key Terms

Rule 10b5-1 Plan, open-market sale, weighted average sale price, price ranges, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $121.67"

price ranges financial

"the range of prices were between $121.13 and $122.13"

common stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mirum Pharmaceuticals (MIRM) CFO Eric Bjerkholt report in this Form 4?

He reported selling 5,000 shares of Mirum Pharmaceuticals common stock in open-market transactions. The trades were executed on July 6, 2026, and were made under a pre-arranged Rule 10b5-1 trading plan disclosed in the filing’s footnotes.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell and at what prices?

Eric Bjerkholt sold a total of 5,000 common shares. Individual transactions were priced around $124.94, $123.84, $122.43, and $121.67 per share, with footnotes providing weighted average prices and price ranges for several of the sale batches.

Does Mirum Pharmaceuticals (MIRM) CFO Eric Bjerkholt still hold shares after these sales?

Yes. After the reported open-market sales, he directly holds 42,181 shares of Mirum Pharmaceuticals common stock. The Form 4 shows this as his post-transaction ownership, indicating the sale represented only a portion of his total direct holdings.

Were the Mirum Pharmaceuticals (MIRM) CFO share sales discretionary or pre-planned?

The filing states the transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. Such plans are pre-arranged trading programs, which typically automate trades according to preset instructions rather than discretionary market timing.

What additional pricing detail does the Mirum Pharmaceuticals (MIRM) Form 4 provide?

Footnotes disclose weighted average sale prices of $121.67, $122.43 and $123.84, with price ranges like $121.13–$122.13 and $123.285–$124.27. The Form 4 notes that detailed breakdowns by exact price level are available upon request to the issuer or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 05:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		3,124	D	$121.67(2)	44,057	D
Common Stock	07/06/2026		S(1)		1,048	D	$122.43(3)	43,009	D
Common Stock	07/06/2026		S(1)		528	D	$123.84(4)	42,481	D
Common Stock	07/06/2026		S(1)		300	D	$124.94	42,181	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.

2. . The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. . The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. . The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Judit Ryvkin, Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)